| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NAGa |
| Uniprot No | P17050 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-411aa |
| 氨基酸序列 | LDNGLLQTPPMGWLAWERFRCNINCDEDPKNCISEQLFMEMADRMAQDGW RDMGYTYLNIDDCWIGGRDASGRLMPDPKRFPHGIPFLADYVHSLGLKLG IYADMGNFTCMGYPGTTLDKVVQDAQTFAEWKVDMLKLDGCFSTPEERAQ GYPKMAAALNATGRPIAFSCSWPAYEGGLPPRVNYSLLADICNLWRNYDD IQDSWWSVLSILNWFVEHQDILQPVAGPGHWNDPDMLLIGNFGLSLEQSR AQMALWTVLAAPLLMSTDLRTISAQNMDILQNPLMIKINQDPLGIQGRRI HKEKSLIEVYMRPLSNKASALVFFSCRTDMPYRYHSSLGQLNFTGSVIYE AQDVYSGDIISGLRDETNFTVIINPSGVVMWYLYPIKNLEMSQQHHHHHH |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NAGa(假设为N-acetylgalactosaminidase或相关重组蛋白)的模拟参考文献示例，内容基于常见研究主题概括，非真实文献数据：
---
1. **文献名称**：*Recombinant NAG-1 Protein Induces Apoptosis in Colon Cancer Cells*
**作者**：Smith J, et al.
**摘要**：研究重组NAG-1蛋白对结肠癌细胞凋亡的调控作用，发现其通过激活caspase通路抑制肿瘤生长，为癌症治疗提供潜在靶点。
2. **文献名称**：*Expression and Purification of Functional NAGa in E. coli*
**作者**：Lee H, Kim S.
**摘要**：报道一种高效的大肠杆菌表达系统，用于重组NAGa蛋白的可溶性表达与纯化，验证了其酶活性及稳定性。
3. **文献名称**：*NAGa Recombinant Protein Attenuates Inflammation in Murine Models*
**作者**：Wang Y, et al.
**摘要**：在小鼠模型中验证重组NAGa蛋白的抗炎作用，表明其通过抑制NF-κB通路减轻炎症反应。
4. **文献名称**：*Structural Characterization of NAGa and Its Role in Glycan Metabolism*
**作者**：Garcia R, et al.
**摘要**：通过X射线晶体学解析NAGa重组蛋白的三维结构，并阐明其在糖代谢中的底物特异性与催化机制。
---
**注**：以上为模拟文献，实际研究中请通过学术数据库(如PubMed、Web of Science)以“NAGa recombinant protein”或相关关键词检索真实文献。
**Background of NAGa Recombinant Proteins**
NAGa (N-acetylgalactosamine) recombinant proteins are engineered biologics designed to leverage the specific binding properties of GalNAc, a carbohydrate moiety, to target receptors such as the asialoglycoprotein receptor (ASGPR) highly expressed on liver cells. This targeting mechanism has made NAGa-conjugated molecules, including recombinant proteins, a cornerstone in liver-directed therapies. Recombinant protein technology enables the production of these proteins by inserting genes encoding desired sequences into host systems (e.g., bacteria, yeast, or mammalian cells), followed by purification and modification with GalNAc residues.
The development of NAGa recombinant proteins stems from the need for targeted drug delivery, enhancing therapeutic efficacy while minimizing off-target effects. ASGPR-mediated endocytosis allows these proteins to be efficiently internalized by hepatocytes, making them ideal for treating liver-specific diseases such as hepatitis, metabolic disorders, or hepatocellular carcinoma. Beyond therapeutics, NAGa recombinant proteins are also used in diagnostic tools and research to study receptor-ligand interactions or carbohydrate biology.
Advancements in glycoengineering and site-specific conjugation techniques have improved the precision and stability of NAGa modifications. These proteins often exhibit prolonged circulation times and reduced immunogenicity compared to non-targeted alternatives. Challenges remain in optimizing binding affinity and scalability, but ongoing innovations in genetic engineering and biomanufacturing continue to expand their applications.
Overall, NAGa recombinant proteins represent a convergence of glycobiology and recombinant technology, offering promising avenues for precision medicine and biologics development.
×
